Aldeyra Therapeutics shares are trading lower after the FDA said it identified substantive review issues in connection with the NDA for reproxalap.
Portfolio Pulse from Benzinga Newsdesk
Aldeyra Therapeutics' shares are trading lower after the FDA identified substantive review issues with the New Drug Application (NDA) for reproxalap.
October 16, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aldeyra Therapeutics' stock is expected to trade lower due to the FDA's identified issues with the NDA for reproxalap.
The FDA's identification of substantive review issues with the NDA for reproxalap is a significant setback for Aldeyra Therapeutics. This negative news is likely to impact investor sentiment and cause a decrease in the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100